Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42567   clinical trials with a EudraCT protocol, of which   7008   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2018-004301-32
    Sponsor's Protocol Code Number:TMC278HTX2002
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2019-06-11
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2018-004301-32
    A.3Full title of the trial
    A Phase 2, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 years) who are Virologically Suppressed
    Estudio en fase II, abierto, de un solo grupo, multicéntrico, para evaluar la farmacocinética, la seguridad, la tolerabilidad y la eficacia de cambiar a RPV más
    otros ARV en niños infectados por el VIH-1 (de 2 a <12 años de edad) que presentan supresión virológica
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 years) who are Virologically Suppressed
    Un estudio clínico para evaluar la farmacocinética, seguridad, tolerabilidad y eficacia del cambio a RPV más otros ARV en niños infectados con VIH-1 (de 2 a 12 años de edad) que que presentan supresión virológica
    A.4.1Sponsor's protocol code numberTMC278HTX2002
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/322/2018
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorJanssen Sciences Ireland UC
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportJanssen Sciences Ireland Unlimited Company
    B.4.2CountryIreland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationJANSSEN CILAG, S.A.
    B.5.2Functional name of contact pointGlobal Clinical Operations Spain
    B.5.3 Address:
    B.5.3.1Street AddressPº de las Doce Estrellas, 5-7
    B.5.3.2Town/ cityMadrid
    B.5.3.3Post code28042
    B.5.3.4CountrySpain
    B.5.4Telephone number0034917228075
    B.5.5Fax number0034917228628
    B.5.6E-mailerodrig4@its.jnj.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Edurant®
    D.2.1.1.2Name of the Marketing Authorisation holderJanssen-Cilag International NV
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRilpivirine
    D.3.2Product code TMC278
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRilpivirine Hydrochloride
    D.3.9.1CAS number 700361-47-3
    D.3.9.2Current sponsor codeTMC278
    D.3.9.3Other descriptive nameR314585
    D.3.9.4EV Substance CodeSUB31460
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRilpivirine hydrochloride
    D.3.2Product code TMC278
    D.3.4Pharmaceutical form Dispersible tablet
    D.3.4.1Specific paediatric formulation Yes
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRilpivirine hydrochloride
    D.3.9.1CAS number 700361-47-3
    D.3.9.2Current sponsor codeTMC278
    D.3.9.3Other descriptive nameRILPIVIRINE HYDROCHLORIDE
    D.3.9.4EV Substance CodeSUB31460
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2.5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    HIV-1 Infection
    Infección por VIH-1
    E.1.1.1Medical condition in easily understood language
    HIV-1 Infection
    Infección por VIH-1
    E.1.1.2Therapeutic area Diseases [C] - Virus Diseases [C02]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level LLT
    E.1.2Classification code 10068341
    E.1.2Term HIV-1 infection
    E.1.2System Organ Class 100000004862
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objectives are:
    • To evaluate the steady-state pharmacokinetics (PK) of rilpivirine and determine the appropriate dose of rilpivirine in combination with other antiretrovirals (ARVs) in participants aged ≥2 to <12 years with a body weight of <25 kg.
    • To evaluate the safety and tolerability of rilpivirine in combination with other ARVs in participants aged ≥2 to <12 years over a 24-week treatment period.
    Los objetivos principales son:
    - Evaluar la farmacocinetica de RPV en el estado de equilibrio y determinar la dosis apropiada de rilpivirina en combinación con otros antirretrovirales (ARV) en participantes de edades comprendidas entre ≥2 y <12 años con un peso corporal de <25 kg.
    - Evaluar la seguridad y la tolerabilidad de la rilpivirina en combinación con otros ARV en participantes de edades comprendidas entre ≥2 y <12 años durante un período de tratamiento de 24 semanas.
    E.2.2Secondary objectives of the trial
    The secondary objectives are:
    • To evaluate the safety and tolerability of rilpivirine in combination with other ARVs over a 48-week treatment period.
    • To evaluate the efficacy of rilpivirine in combination with other ARVs over a 24- and 48-week treatment period.
    • To evaluate population PK and PK/pharmacodynamic (PD) relationships for safety and efficacy of rilpivirine in combination with other ARVs.
    • To assess resistance in case of loss of virologic response to rilpivirine in combination with other ARVs.
    • To evaluate treatment adherence to rilpivirine in combination with other ARVs over a 24 and 48 week treatment period.
    Los objetivos secundarios son:
    - Evaluar la seguridad y tolerabilidad de la rilpivirina en combinación con otros ARV durante un período de tratamiento de 48 semanas.
    - Evaluar la eficacia de la rilpivirina en combinación con otros ARV durante un período de tratamiento de 24 y 48 semanas.
    - Evaluar la FC y las relaciones FC/FD en la poblacion para determinar la seguridad y la eficacia de RPV en combinacion con otros ARV.
    - Evaluar la resistencia en caso de pérdida de la respuesta virológica a la rilpivirina en combinación con otros ARV.
    - Evaluar el cumplimiento del tratamiento con rilpivirina en combinación con otros ARV durante un período de tratamiento de 24 y 48 semanas.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Each potential participant must satisfy all of the following criteria to be enrolled in the study:
    1. Aged ≥2 to <12 years at screening.
    2. Weighing at least 11 kg at screening.
    3. Have documented chronic HIV-1 infection.
    4. Criterion modified per Amendment 1
    4.1 Virologically suppressed on a stable ARV regimen with documented evidence of at least 2 plasma viral loads <50 HIV 1 RNA copies/mL: one within 2-12 months prior to screening and one at screening
    Note: single viral loads ≥50 HIV-1 RNA copies/mL (‘blips’) are allowed after viral suppression (confirmed viral load <50 HIV-1 RNA copies/mL) within 12 months prior to screening, provided a subsequent viral load measurement is <50 HIV-1 RNA copies/mL (or HIV-1 RNA undetectable by a local HIV-1 RNA test) prior to or at screening.
    5. Criterion deleted per Amendment 1.
    6. Parent(s) (preferably both if available or as per local requirements) (or the participant’s legally acceptable representative[s]) must sign an ICF indicating that he or she understands the purpose of and procedures required for the study and is willing to allow the child to participate in the study. Assent is also required from participants capable of understanding the nature of the study (typically aged ≥7 years), as described in the Informed Consent Process in Section 10.3, Appendix 3, Regulatory, Ethical, and Study Oversight Considerations.
    7. Can comply with the protocol requirements.
    8. Can switch from any ARV class.
    9. Never been treated with a therapeutic HIV vaccine.
    10. Otherwise healthy and medically stable on the basis of physical examination, medical history, vital signs, and 12-lead ECG performed at screening. If there are abnormalities, they must be consistent with the underlying illness in the study population. This determination must be recorded in the participant’s source documents and initialed by the investigator.
    Cada participante potencial debe cumplir con todos los siguientes criterios para ser inscrito en el estudio:
    1. Edad ≥2 a <12 años en el momento de la selección.
    2. Pesar al menos 11 kg en el momento de la selección.
    3. Tener una infección crónica documentada por VIH-1.
    4. Criterio modificado según la enmienda 1
    4.1 Suprimidos virológicamente en un régimen estable de ARV con evidencia documentada de al menos 2 cargas virales plasmáticas <50 copias de VIH 1 ARN/mL: una dentro de los 2-12 meses anteriores a la selección y otra durante el periodo de selección.
    Nota: las cargas virales únicas mayor igual a 50 copias ARN VIH/ML (blips o repunte) tras una supresión virológica previa (carga viral confirmada menor 5o copias ARN VIH/ml)se permiten dentro de los 12 meses previos a la seleccion, siempre y cuando exista una medición posterior de la carga viral sea <50 copias de ARN VIH-1/mL (o ARN VIH-1 no detectable por una prueba local de ARN VIH-1) antes o durante la selección.
    5. Criterio eliminado por la enmienda 1.
    6. Los padres (preferiblemente ambos si están disponibles o según requerimientos locales) (o el representante o representantes legalmente aceptables del participante) deben firmar un ICF indicando que entienden el propósito y los procedimientos requeridos para el estudio y que están dispuestos a permitir que el niño participe en el estudio. También se requiere el consentimiento de los participantes capaces de comprender la naturaleza del estudio (generalmente de edad mayor igual a 7 años), tal como se describe en el Proceso de Consentimiento Informado en la Sección 10.3, Apéndice 3, Consideraciones Regulatorias, Éticas y de Supervisión del Estudio.
    7. Puede cumplir con los requisitos del protocolo.
    8. Puede cambiar de cualquier clase de ARV.
    9. Nunca ha sido tratado con una vacuna terapéutica contra el VIH.
    10. Por lo demás, saludable y médicamente estable sobre la base del examen físico, la historia clínica, los signos vitales y el ECG de 12 derivaciones realizado en el momento del cribado. Si hay anormalidades, deben ser consistentes con la enfermedad subyacente en la población del estudio. Esta determinación debe ser registrada en los documentos fuente del participante y firmada por el investigador.
    E.4Principal exclusion criteria
    Any potential participant who meets any of the following criteria will be excluded from participating in the study:
    1. Have previously documented HIV-2 infection.
    2. Have known or suspected acute (primary) HIV-1 infection.
    3. Taken any disallowed concomitant therapies within 4 weeks before the planned first dose of study intervention.
    4. A positive HLA-B*5701 test at screening (when the investigator considers ABC in the background regimen). In case of a positive test, ABC cannot be administered, but instead, the investigator can select another ARV in the background regimen.
    HLA-B*5701 testing is not required for participants with prior documented negative results.
    5. Any current or history of adrenal disorder.
    6. Any active clinically significant diseases (eg, pancreatitis, cardiac dysfunction, active and significant psychiatric disorders, clinical suspicion of adrenal insufficiency, and hepatic impairment) or findings at screening or medical history that, in the investigator’s opinion, would compromise the outcome of the study.
    7. A history of virologic failure to ARVs with or without availability of an HIV-1 genotype result at the time of failure.
    8. Documented genotypic evidence of resistance to RPV or to the selected background ARVs from historical data available in the source documents (ie,at least 1NNRTI RAM from the following list compiled on the basis of the list of the International Antiviral Society United States of America [IAS-USA] NNRTI RAMs and other relevant publications).
    9. A known clinically significant allergy, hypersensitivity, or intolerance to RPV or its excipients or to the selected background ARVs.
    10. Criterion modified per Amendment 1
    10.1 Received an investigational intervention (including investigational vaccines) containing an active substance or used an invasive investigational medical device within 90 days before the planned first dose of study intervention.
    Cualquier participante potencial que cumpla con cualquiera de los siguientes criterios será excluido de participar en el estudio:
    1. Tener una infección por VIH-2 previamente documentada.
    2. Tener o sospechar una infección aguda (primaria) por VIH-1.
    3. Haber tomado cualquier terapia concomitante no permitida dentro de las 4 semanas anteriores a la primera dosis planificada de intervención del estudio.
    4. Una prueba positiva de HLA-B*5701 en el momento del cribado (cuando el investigador considera el ABC en el régimen de fondo). En caso de una prueba positiva, el ABC no puede ser administrado, pero en cambio, el investigador puede seleccionar otro ARV en el régimen de fondo.
    La prueba HLA-B*5701 no es necesaria para los participantes con resultados negativos documentados previamente.
    5. Cualquier historia de trastorno suprarenal previo o actual.
    6. Cualquier enfermedad activa clínicamente significativa (p. ej., pancreatitis, disfunción cardíaca, trastornos psiquiátricos activos y significativos, sospecha clínica de insuficiencia suprarrenal y deterioro hepático) o hallazgos en el examen o historial médico que, en opinión del investigador, comprometerían el resultado del estudio.
    7. Un historial de fracaso virológico de los ARV con o sin disponibilidad de un resultado de genotipo del VIH-1 en el momento del fracaso.
    8. Evidencia genotípica documentada de resistencia al RPV o a los ARVs de fondo seleccionados a partir de datos históricos disponibles en los documentos de fuente (es decir, al menos 1NNRTI RAM de la siguiente lista compilada sobre la base de la lista de la Sociedad Internacional de Antivirales de los Estados Unidos de América[IAS-USA] NNRTI RAMs y otras publicaciones relevantes).
    9. Alergia, hipersensibilidad o intolerancia conocidas clínicamente significativas al RPV o sus excipientes o a los ARV de fondo seleccionados.
    10. Criterio modificado según la enmienda 1
    10.1 Haber recibido una intervención en investigación (incluidas las vacunas en investigación) que contenga un principio activo o haber utilizado un dispositivo médico invasivo en investigación dentro de los 90 días anteriores a la primera dosis planificada de intervención del estudio.
    E.5 End points
    E.5.1Primary end point(s)
    1. Area under the plasma concentration-time curve from time of administration up to 24 hours post dose of rilpivirine, as derived from the intensive PK assessments.
    2. Incidence of grade 3/4 AEs, SAEs, HIV-related events (including acquired immune deficiency syndrome [AIDS]-defining illnesses and Stage-3-defining Opportunistic Illnesses in HIV Infection), and AEs leading to discontinuation of study intervention through 24 weeks of study treatment.
    1. Área bajo la curva de tiempo de concentración plasmática desde el momento de la administración hasta 24 horas después de la dosis de rilpivirina, según se deriva de las evaluaciones intensivas de PK.
    2. Incidencia de EA de grado 3/4, EAE, eventos relacionados con el VIH (incluyendo el síndrome de inmunodeficiencia adquirida[SIDA] - enfermedades que definen la Etapa 3 - definición de las Enfermedades Oportunistas en la Infección por VIH), y EA que conducen a la discontinuación de la intervención del estudio a través de 24 semanas de tratamiento del estudio.
    E.5.1.1Timepoint(s) of evaluation of this end point
    1. From time of administration up to 24 hours postdose of rilpivirine
    2. Until 24 weeks
    1. Desde el momento de la administración hasta 24 horas después de la dosis de rilpivirina
    2. Hasta 24 semanas
    E.5.2Secondary end point(s)
    1. Incidence and severity of AEs/HIV-related events and their relatedness to RPV through 24 and 48 weeks of study treatment.
    2. Change from baseline over time and shift in toxicity grades/abnormalities versus reference for clinical laboratory parameters, ECG parameters, vital signs, and physical examination through 24 and 48 weeks of study treatment.
    3. Proportion of participants with HIV-1 RNA <50 and ≥50 copies/mL using the Food and Drug Administration (FDA) Snapshot approach through 24 and 48 weeks of study treatment.
    4. Immunologic changes, measured by CD4+ cell count (absolute and percentage relative to total lymphocytes), through 24 and 48 weeks of study treatment.
    5. Pharmacokinetic parameters of RPV (other than area under the plasma concentration-time curve [AUC]), as derived from the intensive PK assessments.
    6. Pharmacokinetic parameters of rilpivirine, as derived by population PK modeling, through 24 and 48 weeks of study treatment.
    7. Viral genotype at the time of virologic failure through 24 and 48 weeks of study treatment.
    8. Treatment adherence, as assessed by the Pediatric European Network for the Treatment of AIDS (PENTA) adherence questionnaire and by study intervention accountability, through 24 and 48 weeks of study treatment.
    1. Incidencia y gravedad de los eventos relacionados con EA/VIH y su relación con el virus de la peste bovina durante las 24 y 48 semanas de tratamiento del estudio.
    2. Cambio desde basal a lo largo del tiempo y cambio en los grados/anormalidades de toxicidad versus referencia para los parámetros de laboratorio clínico, parámetros de ECG, signos vitales y examen físico durante las 24 y 48 semanas de tratamiento de estudio.
    3. Proporción de participantes con ARN VIH-1 <50 y ≥50 copias/mL usando el enfoque Snapshot de la Administración de Drogas y Alimentos (FDA) durante las 24 y 48 semanas de tratamiento del estudio.
    4. Cambios inmunológicos, medidos por el recuento de células CD4+ (absoluto y porcentual en relación con el total de linfocitos), durante las 24 y 48 semanas de tratamiento de estudio.
    5. Parámetros farmacocinéticos del RPV (distintos del área bajo la curva de concentración-tiempo de plasma[AUC]), derivados de las evaluaciones intensivas de PK.
    6. Parámetros farmacocinéticos de la rilpivirina, según se deriva del modelado de la población PK, a través de 24 y 48 semanas de tratamiento de estudio.
    7. Genotipo viral en el momento del fracaso virológico a través de 24 y 48 semanas de tratamiento de estudio.
    8. Cumplimiento del tratamiento, según lo evaluado por el cuestionario de cumplimiento de la Red Pediátrica Europea para el Tratamiento del SIDA (PENTA) y por la responsabilidad de la intervención del estudio, a través de 24 y 48 semanas de tratamiento del estudio.
    E.5.2.1Timepoint(s) of evaluation of this end point
    1 to 4, 6 to 8: Through 24 and 48 weeks of study treatment
    1 a 4, 6 a 8: A través de 24 y 48 semanas de tratamiento de estudio
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Tolerability, resistance testing, treatment adherence, resistance-associated mutations (RAMs), RPV intake(only for participants scheduled for an intensive PK visit), treatment adherence, palatability and swallowability assessments
    Tolerabilidad, pruebas de resistencia, adherencia al tratamiento, mutaciones asociadas a la resistencia (MAR), ingesta de RPV (sólo para los participantes programados para una visita intensiva de PK), adherencia al tratamiento, palatabilidad y evaluación de la deglutibilidad.
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA8
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Italy
    Portugal
    Romania
    South Africa
    Spain
    Thailand
    Uganda
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Última visita del último paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months7
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial months12
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 30
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 30
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state10
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 30
    F.4.2.2In the whole clinical trial 30
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Upon study completion, participants will be offered the opportunity to continue study treatment in the pediatric rollover study TMC278IFD3004. Participants who do not roll over in the pediatric study TMC278IFD3004 will be informed that study intervention will not be made available to them after they have completed/discontinued the study intervention phase and that they should return to their primary physician to determine standard of care.
    Una vez finalizado el estudio, se ofrecerá a los participantes la oportunidad de continuar el tratamiento en el estudio de transferencia pediátrica TMC278IFD3004. A los participantes que no participen en el estudio pediátrico TMC278IFD3004 se les informará que la intervención del estudio no estará disponible para ellos después de que hayan completado/descontinuado la fase de intervención del estudio y que deben regresar a su médico de cabecera para determinar el estándar de atención.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-09-16
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-06-25
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA